Monopar Therapeutics presented data from the Phase 2 study (NCT04422431) evaluating ALXN1840 (tiomolibdate choline). The study focused on the drug's effect on liver pathology and clinical symptoms in patients diagnosed with Wilson disease. The presentation occurred at the European Association for the Study of the Liver (EASL) International Liver Congress 2026 on May 29, 2026.